两种胰岛素强化治疗方案治疗2型糖尿病120例  

Two Regimens of Insulin Intensive therapy for Treating 120 Cases of Type 2 Diabetes Mellitus

作　　者：张晓春[1] 丁启强 周燕萍[1] 舒国梅 

机构地区：[1]四川省宜宾市第二人民医院药剂科,四川宜宾644000

出　　处：《中国药业》2012年第17期88-89,共2页China Pharmaceuticals

摘　　要：目的比较诺和锐30与诺和灵N+诺和灵R对2型糖尿病患者血糖控制的疗效及安全性。方法将120例2型糖尿病患者随机分为两组,A组(60例)采用诺和灵N+诺和灵R于睡前及三餐前30 min皮下注射,B组(60例)采用诺和锐30于三餐前皮下注射,比较两组患者治疗达标后三餐前与睡前毛细血管全血血糖水平、糖化血红蛋白、达标后72 h血糖波动范围及低血糖反应发生率。结果两组血糖达标后,三餐前及睡前毛细血管全血血糖水平比较,无统计学差异(P>0.05);B组与A组血糖达标后72 h血糖波动范围比较,差异有统计学意义(P<0.05),B组优于A组;B组较A组的低血糖发生率低,差异有统计学意义(P<0.05)。结论诺和锐30于三餐前10 min皮下注射,较诺和灵N+诺和灵R对2型糖尿病的血糖控制更稳定,使用更安全。Objective To compare the curative effects and safety of BIAsp30 and Novolin N plus Novolin 30R for controlling blood glucose in the patients with type 2 diabetes mellitus （T2DM）. Methods A hundred and twenty cases of T2DM were randomly divided into the group A and B. The group A （60 cases） was given Novolin N plus Novolin 30R by subcutaneous injection before bedtime and at 30 min before three meals. The group B（60 cases） was given BIAsp30 by subcutaneous injection at 30 rain before three meals. The capillary blood glucose levels before 3 meals and before bedtime after reaching standards, glyeosylated hemoglobin （HbAIc）, fluctuation scope of blood glucose within 72 h after reaching standards and the occurrence rate of hypoglycemia were compared between the 2 groups. Results The capillary blood glucose levels before 3 meals and before bedtime after reaching standards had no statistical difference between 2 groups（ P 〉 0.05）. The fluctuation scope of blood glucose within 72 h after reaching standards had statistical difference between 2 groups（ P 〈 0. 05）, the group A was superior to the group B. The occurrence rate of hypoglycemia in the group B was lower than that in the group A with statistical significance（ P 〈0. 05）. Conclusion BIAsp30 by subcutaneous injection at 10 min before 3 meals is more stable and safer than Novolin N plus Novolin 30R for controlling the blood glucose in T2DM.

关 键 词：诺和灵N 诺和灵30R 诺和锐30 强化治疗 2型糖尿病 胰岛素 

分 类 号：R969.4[医药卫生—药理学] R977.15[医药卫生—药学]